Spring 2014 Newsletter!

Our most recent newsletter includes the list of trainees who were awarded a travel award for the Montreal meeting and more! Read it now:
CAN Connection - Spring 2014

CAN connection

Canadian Neuroscience Meeting 2014

Our next meeting will take place May 25 - 28 2014 in Montreal

View the meeting website
You can now:
register at our early-bird rate,
book your room at the Montreal Bonaventure Hilton

CAN Social at SfN in San Diego

Thank you for making the CAN Social at the Hard Rock Hotel in San Diego a great
get-together once again this year.

We were also happy to meet many of you in person at our exhibit booth at SfN, and look forward to seeing you next in Montreal!

CAN invites its members to thank Air France

Air France's commitment to supporting biomedical research is to be commended. Their continued commitment to transporting live animals used for research is very important to neuroscientists.

We invite all our members and neuroscientists everywhere to write to Air France to thank them for this important support. Read more here

Shayna Rosenbaum 2013 CAN Young Investigator Awardee

The Canadian Association for Neuroscience is proud to announce Dr. Shayna Rosenbaum, from York University, is the CAN 2013 Young Investigator Awardee.
Read Dr. Shayna Rosenbaum's profile and find representative publications on the 2013 Award page.

Shayna Rosenbaum

Neuroscience in the Media

Have you listened to the "Think about it: A user's guide to the brain" radio series this Summer on the CBC? All shows are still available: Think about it website

Read "A Big Brainstorm is underway in Neuroscience", by Ivan Semeniuk, in the Globe and Mail (includes interviews with CAN members David Kaplan, Tim Murphy and Yves De Koninck).

Also on the CBC, Henry Friensen Prize winner Marc Tessier
Lavigne was interviewed by Paul Kennedy, host of Ideas.
Listen to Building Brains.


Neuroscience Research Funding Opportunities

Visit our new Funding Opportunities webpage.

The page currently features new funding opportunities from :

Brain Canada - Platform Support Grants

The W. Garfield Weston Foundation 2013 Rapid Response:
Neurodegenerative Diseases of Aging grant program,
and the

International Foundation for Research in Paraplegia.

funding image

CAN President Feature Interview

Sam David, President of the Canadian Association for Neuroscience, has given a feature interview for the magazine International Innovation.

"International Innovation is the leading global dissemination resource for the wider scientific, technology and research communities, dedicated to disseminating the latest science, research and technological innovations on a global level. More information and a complimentary subscription offer to the publication can be found here"

International Innovation Feature

SickKids scientists explain baffling chemo resistance and identify possible therapy for baby brain tumour

Dr. Michael Taylor

Dr. Michael Taylor

There are usually three main tools for fighting brain cancer: surgery, radiation and chemotherapy. But for patients with ependymoma, a type of childhood brain tumour most common in babies, despite many clinical trials none of the standard chemotherapy medicines have been shown to help. While treatments for many other childhood cancers have changed and improved over the past two decades, chemotherapy for ependymoma has remained stagnant. The underlying cause of the chemo-resistance has baffled doctors until now. +++ »

New brain imaging technique allows for a closer look at MS

Yunyan Zhang

Yunyan Zhang

More detailed scans could lead to better diagnosis and treatments

Multiple sclerosis (MS) is an unpredictable and debilitating neurodegenerative disease that affects an estimated 100,000 Canadians. Typically, Magnetic Resonance Imaging (MRI) is used to confirm diagnosis, but current techniques are limited in their ability to detect subtle differences in tissue damage. +++ »

Research reveals new therapeutic targets for Huntington’s and Parkinson’s disease

Stephen Ferguson

Stephen Ferguson

Research from Western University (London, Canada) has revealed a possible new target for treating movement disorders such as Huntington’s disease (HD) and Parkinson’s disease. Stephen Ferguson, PhD, a scientist at Western’s Robarts Research Institute, and Fabiola Ribeiro, PhD, of the Universidade Federal de Minas Gerais in Brazil found a definite improvement in motor behaviours in a HD mouse model when one of the major receptors in the brain, called Metabotropic Glutamate Receptor 5 (mGluR5) was deleted. The research is published online in Human Molecular Genetics. +++ »

How metabolism and brain activity are linked

Dr. Derek Bowie

Dr. Derek Bowie

Study sheds light on why diet may help control seizures in epilepsy patients

A new study by scientists at McGill University and the University of Zurich shows a direct link between metabolism in brain cells and their ability to signal information. The research may explain why the seizures of many epilepsy patients can be controlled by a specially formulated diet. +++ »

Study conducted at Lady Davis Institute reveals new evidence that Caspase-6 is key to the cognitive impairment in Alzheimer’s disease

Andrea Leblanc

Andrea Leblanc

Through a series of studies, Dr. Andréa LeBlanc, a principal investigator at the Lady Davis Institute at the Jewish General Hospital, has discovered elevated levels of the protein Caspase-6 in the area of the brain – namely, the hippocampus, which is responsible for memory and cognition – first damaged by Alzheimer’s disease. This phenomenon is seen from the very earliest stages of cognitive impairment. +++ »

Stopping tumours in their path

Dr. Stephano Stifani

Dr. Stephano Stifani

New study sheds light on most common and deadly form of brain cancer

Glioblastoma (GBM) is the most common and deadly form of primary malignant brain cancer accounting for approximately 15% of all brain tumours and occurring mostly in adults between the ages of 45 and 70. The aggressive recurrent nature of this cancer is only temporarily contained by combined surgery, chemotherapy and radiation treatment. The recurrence of GBM is usually fatal, resulting in an average patient survival time of less than two years. A new study from the Montreal Neurological Institute and Hospital – The Neuro – at McGill University, published in Nature Communications, identifies two specific key players in the growth of GBM. +++ »